ICLR ICON PLC
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1060955
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY5.0%
TTM EPS YoY25.8%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR-2.8%
Margins
Gross margin23.5%
Operating margin5.3%
Net margin5.4%
FCF margin10.3%
EBITDA margin9.7%
Returns
ROE5.0%
ROA2.8%
ROIC (approx.)3.0%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.37x
Current ratio1.32x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income2.29x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.02B | $2.06B | $2.03B | $2.19B | $2.08B | $2.04B | $2.02B | $2.06B |
| Cost of revenue | $1.53B | $1.58B | $1.56B | $1.69B | $1.54B | $1.46B | $1.45B | $1.43B |
| Gross profit | $491.83M | $479.29M | $477.93M | $500.89M | $545.46M | $583.33M | $566.06M | $632.74M |
| SG&A expense | $196.85M | $194.32M | $200.60M | $179.70M | $197.05M | $205.01M | $198.38M | $151.44M |
| Operating income | $198.84M | $137.83M | $173.73M | -$72.51M | -$222.91M | $230.94M | $226.97M | $330.40M |
| Interest expense | $66.17M | $48.79M | $48.00M | $49.49M | $50.24M | $50.15M | $47.61M | $51.43M |
| Pretax income | — | $92.20M | — | $159.85M | -$271.39M | $182.84M | $181.16M | $347.41M |
| Income tax | $32.45M | $19.61M | $22.81M | -$10.36M | $12.79M | -$20.67M | $20.35M | -$12.77M |
| Net income | $122.13M | $72.58M | $104.75M | $149.19M | -$284.18M | $203.52M | $160.81M | $347.09M |
| EBITDA | $293.26M | $228.60M | $264.06M | $17.78M | -$123.88M | $328.66M | $322.93M | $427.05M |
| EPS (basic) | 1.59 | 0.94 | 1.37 | — | -3.67 | 2.57 | 2.00 | — |
| EPS (diluted) | 1.58 | 0.94 | 1.36 | — | -3.67 | 2.56 | 1.99 | — |
| Weighted avg. shares (diluted) | 77.40M | 77.37M | 77.26M | — | 77.37M | 79.55M | 80.92M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $808.98M | $928.38M | $765.16M | $647.29M | $468.89M | $390.40M | $526.70M | $538.78M |
| Short-term investments | — | — | — | $0 | — | — | — | $0 |
| Receivables | $1.51B | $1.46B | $1.47B | $1.47B | $1.39B | $1.37B | $1.39B | $1.39B |
| Current assets | $3.64B | $3.75B | $3.61B | $3.50B | $3.34B | $3.24B | $3.32B | $3.28B |
| PP&E, net | $375.26M | $385.43M | $384.75M | $395.72M | $377.94M | $377.98M | $378.25M | $382.88M |
| Goodwill | $8.72B | $8.72B | $8.73B | $8.73B | $8.73B | $9.09B | $9.07B | $9.05B |
| Intangibles | $3.10B | $3.15B | $3.20B | $3.25B | $3.30B | $3.44B | $3.50B | $3.56B |
| Total assets | $16.24B | $16.40B | $16.32B | $16.27B | $16.16B | $16.54B | $16.64B | $16.63B |
| Current liabilities | $2.77B | $3.93B | $3.17B | $3.20B | $3.23B | $2.55B | $2.68B | $2.64B |
| Long-term debt | $3.38B | $2.11B | $2.87B | $2.87B | $2.88B | $3.38B | $3.39B | $3.40B |
| Total debt | $3.38B | $2.11B | $2.87B | $2.87B | $2.88B | $3.38B | $3.39B | $3.40B |
| Total liabilities | $7.12B | $7.02B | $7.02B | $7.08B | $7.16B | $7.04B | $7.22B | $7.19B |
| Shareholders' equity | $9.13B | $9.38B | $9.30B | $9.19B | $8.99B | $9.50B | $9.43B | $9.44B |
| Net debt | $2.57B | $1.18B | $2.10B | $2.23B | $2.41B | $2.99B | $2.86B | $2.86B |
| Shares outstanding | 74.92M | 77.15M | 76.60M | 76.57M | 76.36M | 77.77M | 79.46M | 80.76M |
| Cash flow statement | ||||||||
| Operating cash flow | $345.14M | $281.27M | $167.01M | $234.16M | $387.60M | $146.20M | $268.24M | $338.31M |
| Capital expenditure | $37.99M | $42.42M | $30.77M | $59.33M | $53.70M | $32.28M | $28.91M | $61.29M |
| Free cash flow | $307.15M | $238.85M | $136.24M | $174.83M | $333.90M | $113.92M | $239.33M | $277.03M |
| Investing cash flow | -$50.58M | -$108.34M | -$39.44M | -$55.94M | -$56.10M | -$38.21M | -$37.28M | -$68.88M |
| Financing cash flow | -$413.76M | -$8.12M | -$6.36M | -$5.79M | -$256.77M | -$255.86M | -$252.83M | -$403.96M |
| Depreciation & amortization | $94.42M | $90.77M | $90.33M | $90.29M | $99.03M | $97.72M | $95.96M | $96.66M |
| Stock-based compensation | $18.01M | $19.44M | $27.57M | $29.51M | $46.19M | $15.43M | $12.36M | $4.69M |
| Share buybacks | $400.00M | $0 | $0 | $0 | $250.00M | $250.00M | $250.00M | $400.00M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.